Rapid generation of NY-ESO-1-specific CD4⁺ T_HELPER1 cells for adoptive T-cell therapy

References

• Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346–57; PMID:15800326; http://dx.doi.org/10.1200/JCO.2005.00.240
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233–9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550–7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 2011; 117:788–97; PMID:21030558; http://dx.doi.org/10.1182/blood-2010-08-299396
   PubMed Web of Science ®Google Scholar
• Kagamu H, Shu S. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 1998; 160:3444–52.
   PubMed Web of Science ®Google Scholar
• Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207:651–67; PMID:20156973; http://dx.doi.org/10.1084/jem.20091921
   PubMed Web of Science ®Google Scholar
• Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 2008; 180:3122–31; PMID:18292535; http://dx.doi.org/10.4049/jimmunol.180.5.3122
   PubMed Web of Science ®Google Scholar
• Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008; 13:507–18; PMID:18538734; http://dx.doi.org/10.1016/j.ccr.2008.04.001
   PubMed Web of Science ®Google Scholar
• Rocken M. Early tumor dissemination, but late metastasis: insights into tumor dormancy. J Clin Invest 2010; 120:1800–3; PMID:20501952; http://dx.doi.org/10.1172/JCI43424
   PubMed Web of Science ®Google Scholar
• Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207:651–67; PMID:20156973; http://dx.doi.org/10.1084/jem.20091921
   PubMed Web of Science ®Google Scholar
• Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109:5346–54; PMID:17327412; http://dx.doi.org/10.1182/blood-2006-10-051318
   PubMed Web of Science ®Google Scholar
• Egeter O, Mocikat R, Ghoreschi K, Dieckmann A, Rocken M. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 2000; 60:1515–20; PMID:10749115
   PubMed Web of Science ®Google Scholar
• Ziegler A, Heidenreich R, Braumuller H, Wolburg H, Weidemann S, Mocikat R, Rocken M. EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood 2009; 113:3494–502; PMID:19188665; http://dx.doi.org/10.1182/blood-2008-08-175109
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641–5; PMID:24812403; http://dx.doi.org/10.1126/science.1251102
   PubMed Web of Science ®Google Scholar
• Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358:2698–703; PMID:18565862; http://dx.doi.org/10.1056/NEJMoa0800251
   PubMed Web of Science ®Google Scholar
• Johnson BD, Jing W, Orentas RJ. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother 2007; 30:203–14; PMID:17471167; http://dx.doi.org/10.1097/01.cji.0000211336.91513.dd
   PubMed Web of Science ®Google Scholar
• Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, Ernestus K, Berthold F. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 2005; 54:400–6; PMID:15449039; http://dx.doi.org/10.1007/s00262-004-0603-z
   PubMed Web of Science ®Google Scholar
• Chen YT, Boyer AD, Viars CS, Tsang S, Old LJ, Arden KC. Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet Cell Genet 1997; 79:237–40; PMID:9605863; http://dx.doi.org/10.1159/000134734
   PubMedGoogle Scholar
• Nakada T, Noguchi Y, Satoh S, Ono T, Saika T, Kurashige T, Gnjatic S, Ritter G, Chen YT, Stockert E, et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun 2003; 3:10
   PubMedGoogle Scholar
• Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003; 63:6076–83; PMID:14522938
   PubMed Web of Science ®Google Scholar
• Ayyoub M, Taub RN, Keohan ML, Hesdorffer M, Metthez G, Memeo L, Mansukhani M, Hibshoosh H, Hesdorffer CS, Valmori D. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004; 4:7
   PubMedGoogle Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323–37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737
   PubMed Web of Science ®Google Scholar
• Valmori D, Souleimanian NE, Hesdorffer CS, Old LJ, Ayyoub M. Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals. Clin Immunol 2005; 117:161–7; PMID:16103015; http://dx.doi.org/10.1016/j.clim.2005.07.004
   PubMedGoogle Scholar
• Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, et al. Functional T cells targeting NY-ESO-1 or melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 2012; 30:1835–41; PMID:22529253
   PubMed Web of Science ®Google Scholar
• Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A 2001; 98:3964–9; PMID:11259659; http://dx.doi.org/10.1073/pnas.061507398
   PubMed Web of Science ®Google Scholar
• Zeng G, Li Y, El-Gamil M, Sidney J, Sette A, Wang RF, Rosenberg SA, Robbins PF. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 2002; 62:3630–5; PMID:12097265
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E, Knuth A, Chen YT, Old LJ. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95:1–30; PMID:16860654; http://dx.doi.org/10.1016/S0065-230X(06)95001-5
   PubMed Web of Science ®Google Scholar
• Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2:933–44; PMID:12461566; http://dx.doi.org/10.1038/nri954
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17:138–46; PMID:8820272; http://dx.doi.org/10.1016/0167-5699(96)80606-2
   PubMedGoogle Scholar
• Tu SP, Quante M, Bhagat G, Takaishi S, Cui G, Yang XD, Muthuplani S, Shibata W, Fox JG, Pritchard DM, et al. IFN-gamma inhibits gastric carcinogenesis by inducing epithelial cell autophagy and T-cell apoptosis. Cancer Res 2011; 71:4247–59; PMID:21512143; http://dx.doi.org/10.1158/0008-5472.CAN-10-4009
   PubMed Web of Science ®Google Scholar
• Liu F, Hu X, Zimmerman M, Waller JL, Wu P, Hayes-Jordan A, Lev D, Liu K. TNFalpha cooperates with IFN-gamma to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis. PloS One 2011; 6:e16241; PMID:21264227; http://dx.doi.org/10.1371/journal.pone.0016241
   PubMedGoogle Scholar
• Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494:361–5; PMID:23376950; http://dx.doi.org/10.1038/nature11824
   PubMed Web of Science ®Google Scholar
• Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637–50; PMID:20156971; http://dx.doi.org/10.1084/jem.20091918
   PubMed Web of Science ®Google Scholar
• Brown DM. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell Immunol 2010; 262:89–95; PMID:20236628; http://dx.doi.org/10.1016/j.cellimm.2010.02.008
   PubMed Web of Science ®Google Scholar
• Wieder T, Braumuller H, Kneilling M, Pichler B, Rocken M. T cell-mediated help against tumors. Cell Cycle 2008; 7:2974–7; PMID:18838866; http://dx.doi.org/10.4161/cc.7.19.6798
   PubMed Web of Science ®Google Scholar
• Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 2008:3122–31; http://dx.doi.org/10.4049/jimmunol.180.5.3122
   PubMed Web of Science ®Google Scholar
• Keller CW, Fokken C, Turville SG, Lunemann A, Schmidt J, Munz C, Lunemann JD. TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. J Biol Chem 2011; 286:3970–80; PMID:20980264; http://dx.doi.org/10.1074/jbc.M110.159392
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29:917–24; PMID:21282551; http://dx.doi.org/10.1200/JCO.2010.32.2537
   PubMed Web of Science ®Google Scholar
• Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, Greil J, Albert MH, Schwinger W, Nathrath M, et al. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 2013; 31:39–48; PMID:23169501; http://dx.doi.org/10.1200/JCO.2011.39.8495
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Opherk K, Bicanic O, Schumm M, Grigoleit GU, Hamprecht K, Jahn G, Handgretinger R, Lang P. Dendritic cell vaccination in an allogeneic stem cell recipient receiving a transplant from a human cytomegalovirus (HCMV)-seronegative donor: induction of a HCMV-specific T(helper) cell response. Cytotherapy 2010; 12:945–50; PMID:20230226; http://dx.doi.org/10.3109/14653241003587645
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041–50; PMID:7655033
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Chen X, Pfeiffer M, Schumm M, Mueller I, Feuchtinger T, Hale G, Lang P. Cellular immune reconstitution after haploidentical transplantation in children. Biol Blood Marrow Transplant 2008; 14:59–65; PMID:18162222; http://dx.doi.org/10.1016/j.bbmt.2007.10.015
   PubMedGoogle Scholar
• Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K, Rubnitz JE, Sandlund JT, Ribeiro RC, Srinivasan A, et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011; 118:223–30; PMID:21613256; http://dx.doi.org/10.1182/blood-2011-01-333070
   PubMed Web of Science ®Google Scholar
• Bethge WA, Faul C, Bornhauser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hagele M, Handgretinger R, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis 2008; 40:13–9; http://dx.doi.org/10.1016/j.bcmd.2007.07.001
   PubMed Web of Science ®Google Scholar
• Kapp M, Stevanovic S, Fick K, Tan SM, Loeffler J, Opitz A, Tonn T, Stuhler G, Einsele H, Grigoleit GU. CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant 2009; 43:399–410; PMID:19139738; http://dx.doi.org/10.1038/bmt.2008.426
   PubMed Web of Science ®Google Scholar
• Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, et al. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 2008; 112:4746–54; PMID:18799724; http://dx.doi.org/10.1182/blood-2008-07-169797
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014; 6:232ra51; PMID:24739759; http://dx.doi.org/10.1126/scitranslmed.3008068
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Richard C, Joachim S, Scheible MH, Schumm M, Hamprecht K, Martin D, Jahn G, Handgretinger R, Lang P. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 2008; 31:199–206; PMID:18481389; http://dx.doi.org/10.1097/CJI.0b013e31815ef862
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27:3135–42; PMID:9464798; http://dx.doi.org/10.1002/eji.1830271209
   PubMed Web of Science ®Google Scholar
• De Rosa SC, Brenchley JM, Roederer M. Beyond six colors: a new era in flow cytometry. Nat Med 2003; 9:112–7; PMID:12514723; http://dx.doi.org/10.1038/nm0103-112
   PubMed Web of Science ®Google Scholar